BioNTech winds down COVID jab manufacturing, shedding staff
BioNTech's plan to shed 22% of its workforce and stop COVID-19 vaccine production has earned it a rebuke from Germany's third-largest labour union.
Newsletters and Deep Dive digital magazine
BioNTech's plan to shed 22% of its workforce and stop COVID-19 vaccine production has earned it a rebuke from Germany's third-largest labour union.
Shares in Novo Nordisk rose this morning after its highly anticipated first-quarter results revealed better-than-expected uptake of oral Wegovy.
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
Axsome's Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA.
Editor's Picks
Newsletters and Deep Dive
digital magazine